Announcements

Job offersmore »





Tweeting Growers

Top 5 - yesterday

Top 5 - last week

Top 5 - last month

Exchange ratesmore »




Inocucor accelerates commercialization with $9.5 million investment

Inocucor uses a patented fermentation process to combine multi-strains of bacteria, yeasts and fungi into powerful biostimulants that naturally improve crop yields, shorten growing periods and create healthier, more resilient soils for farmers and greenhouse growers. A suite of microbial biocontrol products that target devastating diseases in potatoes, tomatoes and strawberries is also under development.

“We’ve come a long way in a few short years, with two products in use in the field, a signature line of biocontrol products under development and hundreds of field trials underway throughout the Americas,” said Inocucor’s President and CEO Donald R. Marvin. “Our business strategy and plan are guided by our vision for a Second Green Revolution for agriculture, one that uses earth-friendly farming products to improve crop yields, revitalize soils and improve water quality.”

Early next spring, Inocucor will occupy its new 30,000-square-foot U.S. headquarters and commercialization office currently under construction in Centennial, Colo. Its Montreal-based, R&D-focused Technical Center of Excellence is currently being enlarged from 10,000 to 20,000 square feet to house expanded product development and manufacturing operations. The company employs about 40 people in Montreal and the U.S., and anticipates adding another 25 to 30 high-level scientific and managerial professionals over the next year.

$9.5 million funding
Inocucor Corporation announced the $9.5 million USD ($12.1M CAD) second close of its Series B financing round. Funds raised to date in its Series B round now total $38.5 million USD ($50.9 million CAD).

The round was led by Pontifax AgTech, a growth capital investor in the global food and agriculture sector.

Other participants in the second Series B round include existing investors Cycle Capital Management (Montreal), Desjardins Innovatech (Montreal) and Cairn Investments (Denver). Inocucor’s first Series B equity financing of $29 million USD ($38.8 million CAD) in March 2017 was led by TPG ART with participation from existing investors.

Funds will enable Inocucor to accelerate its commercialization activities, through the increased production and marketing of its first- and second-generation biostimulant products, Synergro and Synergro Free. They will also advance development of a new suite of biocontrol products that combat economically devastating diseases in high-value crops such as strawberries, tomatoes and potatoes.

For more information
Inocucor


Publication date: 1/9/2018

 


 

Other news in this sector:

2/19/2018 Locations of companies in the Fortune 500 global 2017 list
2/19/2018 AVF gets new Board of Directors
2/19/2018 US: Illumitex and Grow Rebates report record year
2/19/2018 STK appoints Iris Mordechai as VP Human Resources
2/19/2018 Italy: Quality is essential to be successful
2/19/2018 Make your own hydro plant
2/19/2018 US (AL): Layne to lead Auburn’s Department of Horticulture
2/16/2018 Minister from Qatar visits Bom Group
2/16/2018 Mycorrhizal Applications expands sales and customer service capacity
2/16/2018 Bayer to continue work in Russia despite problems over merger
2/16/2018 UK: Guy Thallon joins Business Development team at Fera Science
2/16/2018 Rwanda: Horticulture exporters reaching new markets in Europe
2/15/2018 "Strong cash flow despite challenging global conditions"
2/15/2018 AUSVEG joins NFF Horticulture Council and invests in advocacy
2/15/2018 Syngenta acquires high-resolution satellite imagery innovator FarmShots
2/14/2018 NL: New player on LED market develops their own luminaire
2/14/2018 Lumileds appoints Cheree McAlpine as SVP and General Counsel
2/14/2018 Californian engineering and irrigation companies enter partnership
2/13/2018 BerryWorld unites businesses under single identity
2/13/2018 US (CA): Talley Farms names new sales manager, Derek Sass